Phaseline

Companies › Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals

Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals: clinical trials, targets and expected readouts

3 active drug programs in 3 registered trials: 3 Phase 1; Oncology; next expected readout Jan 2028.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
GTAEXS617–Phase 1Head and Neck Squamous Cell Carcinoma (HNSCC)Jan 2028
EXS73565
unclear - code-named drug candidate for B-cell malignancies
–Phase 1Relapsed or Refractory B-cell MalignanciesJun 2028
EXS74539 (REC-4539)–Phase 1Solid TumorMar 2029

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05985655GTAEXS617Phase 1Head and Neck Squamous Cell Carcinoma (HNSCC)OncologyJan 2028
NCT06980116EXS73565Phase 1Relapsed or Refractory B-cell MalignanciesOncologyJun 2028
NCT07517198EXS74539 (REC-4539)Phase 1Solid TumorOncologyMar 2029

Targets

No annotated target.

Companies with the same targets

–

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.